A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line treatment of patients with non-small cell lung cancer (NSCLC) using change in tumor size (CTS)

Talbot, D; Blackhall, F; Kowalski, D; Ramlau, R; Bepler, G; Grossi, F; Lerchenmuller, C; Pinder, M; Mezger, J; Danson, S; Callies, S; Andre, V; Das, M; Lahn, M; Natale, R

Conference item

A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line treatment of patients with non-small cell lung cancer (NSCLC) using change in tumor size (CTS)

Abstract:: Background: Resistance to chemotherapy in progressive NSCLC is associated with overexpression of antiapoptotic proteins including survivin. Down-regulation of survivin can sensitize NSCLC to DO in vitro and in xenograft studies. On the basis of preclinical/phase I results we examined antitumor activity of DO+LY compared with DO alone. Methods: Key eligibility criteria: ECOG PS 0-1, stage IIIB/IV NSCLC all histologies, progression after first-line platinum regimen. Patients rando... Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Talbot, D., Blackhall, F., Kowalski, D., Ramlau, R., Bepler, G., Grossi, F., Lerchenmuller, C., Pinder, M., Mezger, J., Danson, S., Callies, S., Andre, V., Das, M., Lahn, M., & Natale, R. (2013). A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line treatment of patients with non-small cell lung cancer (NSCLC) using change in tumor size (CTS). Journal of Clinical Oncology, 31(15_suppl.).

MLA Style

Talbot, D., et al. “A Randomized Open-Label Phase II Study Evaluating Antitumor Activity of the Survivin Antisense Oligonucleotide LY2181308 (LY) in Combination with Docetaxel (DO) for Second-Line Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) Using Change in Tumor Size (CTS).” Journal of Clinical Oncology, vol. 31, no. 15_suppl., American Society of Clinical Oncology, 2013.

Chicago Style

Talbot, D, F Blackhall, D Kowalski, R Ramlau, G Bepler, F Grossi, C Lerchenmuller, et al. 2013. “A Randomized Open-Label Phase II Study Evaluating Antitumor Activity of the Survivin Antisense Oligonucleotide LY2181308 (LY) in Combination with Docetaxel (DO) for Second-Line Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) Using Change in Tumor Size (CTS).” In Journal of Clinical Oncology. Vol. 31. American Society of Clinical Oncology.
Tweet
Print